EGFR-TKIs, such as gefitinib, the first or second generation EGFR TKIs, [50,51] and osimertinib, a third-generation EGFR-TKI, [25] have been shown in numerous advanced clinical trials to improve PFS in patients with NSCLC who have an EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.